

OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person * <u>Joyce Roby</u> _____ (Last) (First) (Middle) C/O BIOAFFINITY TECHNOLOGIES, INC. 22211 WEST INTERSTATE 10, SUITE 1206 _____ (Street) SAN ANTONIO, TX 78257 _____ (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>bioAffinity Technologies, Inc. [BIAF]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>10/01/2023</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	10/01/2023		A		11,867 ⁽¹⁾	A	\$1.58	11,867	D	
Common Stock	01/01/2024		A		12,668 ⁽²⁾	A	\$1.48	24,535	D	
Common Stock								583,130	I	The Joyce Living Trust ⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					

1. Name and Address of Reporting Person *

Joyce Roby

(Last) (First) (Middle)

C/O BIOAFFINITY TECHNOLOGIES, INC.

22211 WEST INTERSTATE 10, SUITE 1206

(Street)

SAN ANTONIO, TX 78257

(City) (State) (Zip)

1. Name and Address of Reporting Person *

Joyce Living Trust

(Last) (First) (Middle)

C/O BIOAFFINITY TECHNOLOGIES, INC.

22211 WEST INTERSTATE 10, SUITE 1206

(Street)

SAN ANTONIO, TX 78257

(City) (State) (Zip)

Explanation of Responses:

1. Represents a grant from the Issuer to Dr. Joyce of 11,867 restricted shares of Common Stock, on October 1, 2023 under the Issuer's 2014 Equity Incentive Plan, which shares of restricted stock will vest ratably over three months of continued service beginning on the date of grant and which represents a restricted stock award valued at \$18,750 granted by the Issuer to each of its directors each quarter during the calendar year
2. Represents a grant from the Issuer to Dr. Joyce of 12,668 restricted shares of Common Stock, on January 1, 2024 under the Issuer's 2014 Equity Incentive Plan, which shares of restricted stock will vest ratably over three months of continued service beginning on the date of grant and which represents a restricted stock award valued at \$18,750 granted by the Issuer to each of its directors each quarter during the calendar year.
3. Dr. Joyce is the co-Trustee of The Joyce Living Trust (the "Trust"), together with his wife, Joyce M. Joyce, each of whom may act unilaterally with regard to voting and disposition power with respect to the shares owned by the Trust. Dr. Joyce and Mrs. Joyce are the beneficiaries of the Trust.

/s/ Maria Zannes, Attorney-in-fact 01/24/2024
for Roby Joyce

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.